![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
News & Events | Press ReleasesSionex Corporation Participates in Consortium Awarded a $25 Million NIH Grant for Mass Screening of Radiation Exposure BEDFORD, Mass., September 14, 2005 - Sionex Corporation, a high technology company focused on commercializing breakthrough chemical and biological sensor chips and systems based on its proprietary microDMx™ detection technology, today announced that it is participating in a consortium which has been awarded a $25 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID) through the National Institutes of Health (NIH). The consortium, headed by Columbia University Medical Center, has been awarded a major grant to develop new technologies to rapidly screen large numbers of people for radiation exposure in the event of a terrorist attack on a nuclear facility or detonation of a radiological "dirty bomb". "We are delighted that our proposed technologies have been selected for this grant to help provide rapid, targeted triage following a radiation event," said David J. Brenner, Ph.D., D.Sc., professor of radiation oncology and public health, Center for Radiological Research, Columbia University College of Physicians and Surgeons. Dr. Brenner is the principal investigator of the consortium. Over the next five years, the team will develop new devices that can assess, rapidly following a potentially catastrophic radiological incident, the radiation doses received by hundreds of thousands of individuals. "The role of Sionex in this consortium is to lead the development and commercialization of a handheld device for non-invasive screening for radiation exposure," said Anthony D. Bashall, VP of Marketing & Business Development at Sionex Corporation. "The device will analyze sweat, urine or saliva samples to detect and identify metabolites which are indicative of radiation exposure. Our proprietary technology is currently being used to detect chemical & biological warfare agents, explosives, toxic compounds and narcotics with low cost handheld or highly portable devices." The eight participants involved in the research consortium are: Columbia University Medical Center (lead institution); Harvard University School of Public Health; Arizona State University's Biodesign Institute; the National Cancer Institute; University of Pittsburgh Medical Center; Translational Genomics Research Institute; Sionex Corporation; and the City of New York Department of Health and Mental Hygiene. About Sionex Corporation EDITORIAL CONTACTS: Agency Contact: Forward-looking Statement microDMx is a trademark of Sionex Corporation. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| © 2007 SIONEX Corporation |
||